PFA Pension Forsikringsaktieselskab Makes New Investment in Zoetis Inc. $ZTS

PFA Pension Forsikringsaktieselskab bought a new position in Zoetis Inc. (NYSE:ZTS) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund bought 395,623 shares of the company’s stock, valued at approximately $50,011,000.

A number of other large investors have also added to or reduced their stakes in ZTS. Global Wealth Strategies & Associates bought a new stake in Zoetis in the 4th quarter worth approximately $25,000. Lodestone Wealth Management LLC bought a new stake in Zoetis in the 4th quarter worth approximately $30,000. KERR FINANCIAL PLANNING Corp bought a new stake in Zoetis in the 3rd quarter worth approximately $31,000. Holos Integrated Wealth LLC bought a new stake in Zoetis in the 4th quarter worth approximately $32,000. Finally, Board of the Pension Protection Fund bought a new stake in Zoetis in the 4th quarter worth approximately $38,000. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on ZTS. Weiss Ratings downgraded shares of Zoetis from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Friday, March 27th. William Blair reissued an “outperform” rating on shares of Zoetis in a research report on Monday, March 2nd. UBS Group cut their price objective on shares of Zoetis from $136.00 to $130.00 and set a “neutral” rating for the company in a research report on Tuesday, April 28th. Bank of America boosted their price objective on shares of Zoetis from $135.00 to $140.00 and gave the company a “neutral” rating in a research report on Friday, February 13th. Finally, Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research report on Saturday. Seven equities research analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $151.75.

Zoetis Stock Down 0.7%

ZTS opened at $114.22 on Friday. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03. Zoetis Inc. has a fifty-two week low of $112.97 and a fifty-two week high of $172.23. The firm’s fifty day moving average is $119.93 and its 200 day moving average is $124.67. The stock has a market cap of $48.05 billion, a price-to-earnings ratio of 18.97, a price-to-earnings-growth ratio of 1.76 and a beta of 0.87.

Zoetis (NYSE:ZTS) last released its earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The company had revenue of $2.39 billion for the quarter, compared to analysts’ expectations of $2.36 billion. During the same quarter in the previous year, the company earned $1.40 EPS. Zoetis’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 7.01 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be paid a dividend of $0.53 per share. The ex-dividend date is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.9%. Zoetis’s payout ratio is 35.22%.

Zoetis Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.